Getein Biotech(SH:603387) Xin Lang Cai Jing·2025-10-30 13:13Core Viewpoint - 基蛋生物 is a leading company in the in vitro diagnostics sector in China, showcasing significant investment value due to its comprehensive industry chain advantages [1] Group 1: Business Performance - In Q3 2025, 基蛋生物 reported revenue of 758 million yuan, ranking 14th among 39 companies in the industry, with the top company generating 3.428 billion yuan [2] - The company's net profit for the same period was 150 million yuan, placing it 9th in the industry, while the leading company reported a net profit of 1.588 billion yuan [2] - The revenue from self-developed products was 446 million yuan, accounting for 87.08% of total revenue, while other revenue sources contributed 66.22 million yuan, or 12.92% [2] Group 2: Financial Ratios - As of Q3 2025, 基蛋生物's asset-liability ratio was 26.98%, down from 30.26% year-on-year, which is higher than the industry average of 18.29% [3] - The gross profit margin for the same period was 68.93%, slightly down from 69.43% year-on-year, but still above the industry average of 56.20% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 4.22% to 25,200, while the average number of shares held per shareholder increased by 4.40% to 20,100 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third largest, holding 12.8725 million shares, an increase of 7.1047 million shares from the previous period [5] Group 4: Executive Compensation - The chairman and general manager, 苏恩本, received a salary of 1.746 million yuan in 2024, which remained unchanged from 2023 [4]